Table 3. Outcomes in Genetic Groups.

Gene	Genotype	CND (+)	CND (−)	Unadjusted	Adjusteda
SNP (rs#)		N (%)	N (%)	P-value	OR (95% CI)	P-value
	Overall					0.138
CYP4F2	TT	77 (60.6)	50 (39.4)	0.223	Reference	—
g.4593T>C	TC	59 (56.7)	45 (43.3)		0.82 (0.46–1.44)	0.482
(rs3093089)b	CC	16 (44.4)	20 (55.6)		0.44 (0.20–0.99)	0.047*
	C-carriers	75 (53.6)	65 (46.4)	0.245	0.70 (0.41–1.17)	0.175
Gene	Genotype	MRS3 (3–6)	MRS3 (0–2)	Unadjusted	Adjusteda
SNP (rs#)		N (%)	N (%)	P-value	OR (95% CI)	P-value
	Overall					0.025*
CYP4A11	GG	31 (23)	106 (77)	0.004*	Reference	—
g.13414G>C	GC	31 (42)	43 (58)		2.43 (1.28–4.62)	0.007*
(rs3890011)b	CC	0 (0)	6 (100)		—	0.999
	C-carriers	31 (39)	49 (61)	0.011*	2.12 (1.13–3.99)	0.019*
	Overall					0.055
CYP4F2	AA	22 (40)	33 (60)	0.08	Reference	—
g.4211A>T	TA	25 (23)	82 (77)		0.42 (0.2–0.89)	0.023*
(rs3093156)b	TT	15 (27)	41 (73)		0.44 (0.19–1.03)	0.059
	T-carriers	40 (25)	123 (75)	0.028*	0.43 (0.21–0.85)	0.016*
	Overall					0.055
CYP4F2	CC	23 (25)	69 (75)	0.088	Reference	—
g.8575C>T	CT	26 (26)	74 (74)		1.21 (0.61–2.41)	0.579
(rs3093168)b	TT	12 (46)	14 (54)		3.30 (1.23–8.83)	0.017*
	T-carriers	38 (30)	88 (70)	0.402	1.51 (0.8–2.88)	0.206
Gene	Genotype	MRS12 (3–6)	MRS12 (0–2)	Unadjusted	Adjusteda
SNP (rs#)		N (%)	N (%)	P-value	OR (95% CI)	P-value
	Overall					0.067
CYP4A11	GG	29 (21)	108 (79)	0.007*	Reference	—
g.13414G>C	GC	27 (40)	41 (61)		2.22 (1.13–4.34)	0.020*
(rs3890011)b	CC	0 (0)	5 (100)		—	0.999
	C-carriers	27 (37)	46 (63)	0.014*	1.99 (1.03–3.86)	0.042*

^aMultivariate analysis included correction for age, sex, race, and either Fisher grade (for acute outcomes) or Hunt & Hess score (for long-term outcomes).

^bTagging SNP, DCI, delayed cerebral ischemia; CND, clinical neurological deterioration; MRS, Modified Rankin Scale score at 3 and 12 months: Unfavorable (3–6), Favorable (0–2); *Statistical significance established at *P<0.05 or **P<0.0042 (for multiple comparison correction).